Others before Samumed have tried to drug the Wnt pathway, but found out, in Kibar’s words, that “safety and efficacy were mutually exclusive.” So why does Samumed think it will succeed where others have failed?
One word: targets.
Targeting Wnt can be tricky, Kibar said, “because Wnt...